US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORUKA THERAPEUTICS INC

25.51

+1.024.14%

Post-market: 26.000.4950+1.94%19:42 EDT

Volume:538.08K

Turnover:13.58M

Market Cap:1.23B

PE:-11.90

High:26.19

Open:25.36

Low:24.46

Close:24.49

52wk High:31.13

52wk Low:5.49

Shares:48.38M

Float Shares:22.41M

Volume Ratio:0.91

T/O Rate:2.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1429

EPS(LYR):-3.8737

ROE:--

ROA:--

PB:3.62

PE(LYR):-6.58

Loading ...

Overview Company News Filings

Oruka Therapeutics (ORKA) Has a New Rating from Barclays

Leerink Partners Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

BRIEF-Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC Filing

Oruka Therapeutics Inc: Files for Mixed Shelf of Upto $500 Mln - SEC Filing

THOMSON REUTERS

Oruka Therapeutics files to sell 39.43M shares of common stock for holders

Oruka Therapeutics Up Nearly 30%, on Pace for Largest Percent Increase Since April 2024 -- Data Talk

Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis

Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news

Oruka Therapeutics jumps 28% after MoonLake data miss

Oruka Therapeutics (ORKA) Gets a Buy from LifeSci Capital

Oruka Therapeutics Secures $180 Million in Private Placement Led by Viking Global Investors

Oruka Therapeutics Inc : Btig Raises Target Price to $56 From $44

THOMSON REUTERS

BTIG Remains a Buy on Oruka Therapeutics (ORKA)

Oruka Therapeutics Stock (ORKA) Soars on New Psoriasis Drug That Could Challenge AbbVie (ABBV)

Oruka Therapeutics Shares Jump 20% to Eight-Month High After Co Announces Positive Early-Stage Study Results for Its Experimental Psoriasis Drug

THOMSON REUTERS

Press Release: Oruka Therapeutics Announces $180 Million Private Placement

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Oruka Therapeutics Reports Q2 2025 Financials: Net Loss Widens to $24.6M, Driven by Increased Stock-Based Compensation

Oruka Therapeutics Inc - Q2 EPS $-0.46

THOMSON REUTERS

Oruka Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ORKA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORKA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":25.505,"timestamp":1760385600000,"preClose":24.49,"halted":0,"volume":538080,"hourTrading":{"tag":"盘后","latestPrice":26,"preClose":25.505,"latestTime":"19:42 EDT","volume":2768,"amount":70692.875,"timestamp":1760398945698},"delay":0,"floatShares":22408091,"shares":48384150,"eps":-2.142931,"marketStatus":"Closed","change":1.015,"latestTime":"10-13 16:00:00 EDT","open":25.36,"high":26.185,"low":24.46,"amount":13582316.51904,"amplitude":0.070437,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.142931,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760428800000},"marketStatusCode":5,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":24.49,"preHourTrading":{"tag":"盘前","latestPrice":26.9,"preClose":24.49,"latestTime":"09:25 EDT","volume":27,"amount":697.550022,"timestamp":1760361909057},"postHourTrading":{"tag":"盘后","latestPrice":26,"preClose":25.505,"latestTime":"19:42 EDT","volume":2768,"amount":70692.875,"timestamp":1760398945698},"volumeRatio":0.907718,"impliedVol":0.8763,"impliedVolPercentile":0.5912},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","floatShares":22408091,"roa":"--","roe":"--","lyrEps":-3.873702,"volumeRatio":0.907718,"shares":48384150,"dividePrice":0,"high":26.185,"amplitude":0.070437,"preClose":24.49,"low":24.46,"week52Low":5.485,"pbRate":"3.62","week52High":31.13,"institutionHeld":0.9835,"latestPrice":25.505,"eps":-2.142931,"divideRate":0,"volume":538080,"delay":0,"ttmEps":-2.142931,"open":25.36,"prevYearClose":19.39,"prevWeekClose":24.49,"prevMonthClose":19.23,"prevQuarterClose":19.23,"fiveDayClose":20.33,"twentyDayClose":15.26,"sixtyDayClose":14.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORKA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-03","symbol":"ORKA","defaultRemindTime":1725370200000,"type":"split","dateTimestamp":1725336000000,"forFactor":12,"toFactor":1,"ratio":12},{"date":"2024-08-29","symbol":"ORKA","amount":1.613,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-26","defaultRemindTime":1724938200000,"name":"方舟生物医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-28","payableDate":"2024-08-26","currency":"USD","dateTimestamp":1724904000000,"payDate":"2024-08-28"},{"market":"US","date":"2024-08-01","symbol":"ORKA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722484800000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-04-25","symbol":"ORKA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2024-02-01","symbol":"ORKA","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORKA\",market:\"US\",,,undefined,":[{"executeDate":"2024-08-29","recordDate":"2024-08-26","paymentDate":"2024-08-28","value":1.613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORKA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":10,"updateTime":1755748800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ORKA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ORKA","date":"2025-10-10","current":-11.848258,"percent":0,"low":-11.49024,"twenty":-5.309118,"median":-4.714571,"eighty":-3.994896,"high":-2.779284,"avg":-4.746632,"sd":1.011255,"marketCap":1236215032},"quantilePoints":[{"date":"2025-03-14","current":-4.566552,"twenty":-4.600166,"median":-4.533759,"eighty":-4.155287,"marketCap":417087281},{"date":"2025-03-21","current":-4.898591,"twenty":-4.788731,"median":-4.634189,"eighty":-4.465422,"marketCap":447414094},{"date":"2025-03-28","current":-4.898591,"twenty":-4.90187,"median":-4.734621,"eighty":-4.543597,"marketCap":447414094},{"date":"2025-04-04","current":-3.656521,"twenty":-4.90187,"median":-4.68543,"eighty":-4.155287,"marketCap":333969349},{"date":"2025-04-11","current":-3.021139,"twenty":-4.898591,"median":-4.546056,"eighty":-3.567158,"marketCap":275936558},{"date":"2025-04-17","current":-3.529445,"twenty":-4.883833,"median":-4.205819,"eighty":-3.28595,"marketCap":322362791},{"date":"2025-04-25","current":-4.304201,"twenty":-4.810047,"median":-4.25501,"eighty":-3.440082,"marketCap":393125355},{"date":"2025-05-02","current":-4.136132,"twenty":-4.747739,"median":-4.214018,"eighty":-3.521247,"marketCap":377774745},{"date":"2025-05-09","current":-3.996758,"twenty":-4.714945,"median":-4.198946,"eighty":-3.605691,"marketCap":365044972},{"date":"2025-05-16","current":-3.364967,"twenty":-4.682151,"median":-4.136132,"eighty":-3.605691,"marketCap":354187224},{"date":"2025-05-23","current":-3.980336,"twenty":-4.607544,"median":-4.002451,"eighty":-3.625269,"marketCap":418959306},{"date":"2025-05-30","current":-4.215101,"twenty":-4.558354,"median":-4.038702,"eighty":-3.660839,"marketCap":443670043},{"date":"2025-06-06","current":-4.336041,"twenty":-4.541137,"median":-4.079934,"eighty":-3.705732,"marketCap":456399816},{"date":"2025-06-13","current":-4.57792,"twenty":-4.558354,"median":-4.136132,"eighty":-3.769048,"marketCap":481859363},{"date":"2025-06-20","current":-4.261343,"twenty":-4.543597,"median":-4.170639,"eighty":-3.777968,"marketCap":448537309},{"date":"2025-06-27","current":-4.136846,"twenty":-4.523383,"median":-4.154632,"eighty":-3.785238,"marketCap":435433131},{"date":"2025-07-03","current":-4.48188,"twenty":-4.48188,"median":-4.154632,"eighty":-3.808193,"marketCap":471750426},{"date":"2025-07-11","current":-5.004766,"twenty":-4.566552,"median":-4.184867,"eighty":-3.812292,"marketCap":526787975},{"date":"2025-07-18","current":-5.463625,"twenty":-4.701827,"median":-4.197316,"eighty":-3.861483,"marketCap":575086233},{"date":"2025-07-25","current":-5.061679,"twenty":-4.767415,"median":-4.21456,"eighty":-3.877182,"marketCap":532778457},{"date":"2025-08-01","current":-4.834028,"twenty":-4.898055,"median":-4.257786,"eighty":-3.894967,"marketCap":508816530},{"date":"2025-08-08","current":-4.862484,"twenty":-4.898591,"median":-4.281656,"eighty":-3.898524,"marketCap":511811771},{"date":"2025-08-15","current":-5.221398,"twenty":-4.905169,"median":-4.336041,"eighty":-3.910674,"marketCap":561761175},{"date":"2025-08-22","current":-5.148299,"twenty":-5.001209,"median":-4.36364,"eighty":-3.910674,"marketCap":553896518},{"date":"2025-08-29","current":-5.315383,"twenty":-5.050833,"median":-4.460538,"eighty":-3.918873,"marketCap":571872876},{"date":"2025-09-05","current":-5.210955,"twenty":-5.062675,"median":-4.474766,"eighty":-3.936742,"marketCap":560637652},{"date":"2025-09-12","current":-5.621705,"twenty":-5.07235,"median":-4.48188,"eighty":-3.943016,"marketCap":604829531},{"date":"2025-09-19","current":-5.771385,"twenty":-5.152476,"median":-4.546056,"eighty":-3.972962,"marketCap":620933352},{"date":"2025-09-26","current":-5.238803,"twenty":-5.191462,"median":-4.609934,"eighty":-3.980356,"marketCap":563633712},{"date":"2025-10-03","current":-6.676428,"twenty":-5.243928,"median":-4.669033,"eighty":-3.986032,"marketCap":718305289},{"date":"2025-10-10","current":-11.49024,"twenty":-5.309118,"median":-4.714571,"eighty":-3.994896,"marketCap":1236215032}],"updateTime":1760377895140},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORKA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575422331","title":"Oruka Therapeutics (ORKA) Has a New Rating from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2575422331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575422331?lang=en_us&edition=fundamental","pubTime":"2025-10-13 14:15","pubTimestamp":1760336130,"startTime":"0","endTime":"0","summary":"In a report released on October 10, from Barclays initiated coverage with a Buy rating on Oruka Therapeutics and a price target of $48.00. The comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-has-a-new-rating-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-has-a-new-rating-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2574746285","title":"Leerink Partners Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2574746285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574746285?lang=en_us&edition=fundamental","pubTime":"2025-10-12 09:05","pubTimestamp":1760231132,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst David Risinger reiterated a Buy rating on Oruka Therapeutics on October 8. The company’s shares closed last Friday at $24....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2572636429","title":"BRIEF-Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636429?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:31","pubTimestamp":1759527101,"startTime":"0","endTime":"0","summary":"BRIEF-Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC FilingOct 3  - Oruka Therapeutics Inc ORKA.O:ORUKA THERAPEUTICS INC: FILES FOR MIXED SHELF OF UPTO $500 MILLION - SEC FILINGSource text: [ID:n0001213900-25-096198]Further company coverage: ORKA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nFWN3VK0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2572636433","title":"Oruka Therapeutics Inc: Files for Mixed Shelf of Upto $500 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636433?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:30","pubTimestamp":1759527013,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nFWN3VK0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2572636058","title":"Oruka Therapeutics files to sell 39.43M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636058","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636058?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:25","pubTimestamp":1759526706,"startTime":"0","endTime":"0","summary":"17:21 EDT Oruka Therapeutics (ORKA) files to sell 39.43M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-files-to-sell-39-43m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-files-to-sell-39-43m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","BK4539","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2571351966","title":"Oruka Therapeutics Up Nearly 30%, on Pace for Largest Percent Increase Since April 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2571351966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571351966?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:02","pubTimestamp":1759168920,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics, Inc.  is currently at $19.72, up $4.52 or 29.74%. --Would be highest close since Jan. 6, 2025, when it closed at $20.52. --On pace for largest percent increase since April 3, 2024, when it rose 90.06%. --Currently up two consecutive days; up 31.03% over this period. --Up 33.24% month-to-date; on pace for best month since April 2024, when it rose 98.3%. --Down 100% from its all-time closing high of $68720424.00 on Feb. 18, 2000. --Down 19.54% from 52 weeks ago , when it closed at $24.51. --Up 190.86% from its 52-week closing low of $6.78 on April 8, 2025. --Traded as high as $19.99; highest intraday level since Jan. 7, 2025, when it hit $20.88","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","ORKA","BK4139"],"gpt_icon":0},{"id":"2571593273","title":"Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2571593273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571593273?lang=en_us&edition=fundamental","pubTime":"2025-09-30 01:15","pubTimestamp":1759166127,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on September 27. David Risinger has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oruka-therapeutics-orka-002-promising-alternative-with-competitive-edge-in-hidradenitis-suppurativa-and-psoriasis-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oruka-therapeutics-orka-002-promising-alternative-with-competitive-edge-in-hidradenitis-suppurativa-and-psoriasis-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2571435934","title":"Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news","url":"https://stock-news.laohu8.com/highlight/detail?id=2571435934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571435934?lang=en_us&edition=fundamental","pubTime":"2025-09-30 01:10","pubTimestamp":1759165808,"startTime":"0","endTime":"0","summary":"Leerink expects Oruka Therapeutics (ORKA) shares to trade higher following MoonLake Immunotherapeutics’ (MLTX) disclosure of mixed Phase 3 results ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leerink-sees-greater-opportunity-for-orukas-orka-002-after-moonlake-news-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leerink-sees-greater-opportunity-for-orukas-orka-002-after-moonlake-news-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2571356960","title":"Oruka Therapeutics jumps 28% after MoonLake data miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2571356960","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571356960?lang=en_us&edition=fundamental","pubTime":"2025-09-30 00:50","pubTimestamp":1759164615,"startTime":"0","endTime":"0","summary":"Shares of Oruka Therapeutics (ORKA) are up 28%, or $4.31, to $19.51 in midday trading after MoonLake Immunotherapeutics (MLTX) reported that sonelo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-jumps-28-after-moonlake-data-miss-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-jumps-28-after-moonlake-data-miss-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","BK4139","MLTX","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2570989918","title":"Oruka Therapeutics (ORKA) Gets a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2570989918","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570989918?lang=en_us&edition=fundamental","pubTime":"2025-09-27 22:35","pubTimestamp":1758983709,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics, with a price target of $41.00. The comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-lifesci-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-lifesci-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2569071165","title":"Oruka Therapeutics Secures $180 Million in Private Placement Led by Viking Global Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2569071165","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569071165?lang=en_us&edition=fundamental","pubTime":"2025-09-23 23:24","pubTimestamp":1758641047,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics, Inc., a biotechnology company focused on developing novel biologics for chronic skin diseases, has announced a private investment in public equity  financing, expected to result in gross proceeds of approximately $180 million. The financing was led by Viking Global Investors with participation from new and existing investors such as Affinity Healthcare Fund, Blackstone Multi-Asset Investing, and others. Jefferies, TD Cowen, Guggenheim Securities, and LifeSci Capital are acting as joint placement agents. Oruka is selling 10,933,405 shares of its common stock at $15.00 per share and pre-funded warrants to purchase 1,066,666 shares of common stock at $14.999 per warrant. The financing is anticipated to close around September 19, 2025, pending customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL1XgjwS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2568423722","title":"Oruka Therapeutics Inc : Btig Raises Target Price to $56 From $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2568423722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568423722?lang=en_us&edition=fundamental","pubTime":"2025-09-18 13:48","pubTimestamp":1758174533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250918:nFWN3V50AW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2568443010","title":"BTIG Remains a Buy on Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568443010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568443010?lang=en_us&edition=fundamental","pubTime":"2025-09-18 07:45","pubTimestamp":1758152714,"startTime":"0","endTime":"0","summary":"In a report released today, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a price target of $56.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2568494996","title":"Oruka Therapeutics Stock (ORKA) Soars on New Psoriasis Drug That Could Challenge AbbVie (ABBV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568494996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568494996?lang=en_us&edition=fundamental","pubTime":"2025-09-17 21:58","pubTimestamp":1758117526,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics stock was up on Wednesday alongside positive drug data and a $180 million private placement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/oruka-therapeutics-stock-orka-soars-on-new-psoriasis-drug-that-could-challenge-abbvie-abbv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/oruka-therapeutics-stock-orka-soars-on-new-psoriasis-drug-that-could-challenge-abbvie-abbv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1037948541.HKD","IE00BDGV0183.EUR","LU1244550494.USD","IE00BJJMRZ35.SGD","BK4559","ABBV","LU1989772840.SGD","LU0661504455.SGD","IE00BJT1NW94.SGD","LU1934455194.USD","BK4533","LU1037948897.HKD","LU1929549753.HKD","LU1989771016.USD","LU2237443978.SGD","LU0289739699.SGD","LU2468319806.SGD","LU2237443622.USD","LU0545039389.USD","LU0820561909.HKD","LU0310799852.SGD","LU2237443549.SGD","LU2087621335.USD","LU0738911758.USD","LU0985320562.USD","LU1989772923.USD","LU2089984988.USD","LU0256863811.USD","LU1023059063.AUD","LU0965508806.USD","LU0198837287.USD","LU0058720904.USD","SG9999015978.USD","LU1003077747.HKD","LU0417517546.SGD","LU0211328371.USD","ORKA","LU1934455863.HKD","LU1093756325.SGD","LU0256863902.USD","LU2237443382.USD","LU2237443895.HKD","LU1934455277.USD","LU0553294199.USD","SG9999001440.SGD","IE00B19Z3B42.SGD","BK4585","LU1093756168.USD","IE0004445239.USD","LU1244550221.USD"],"gpt_icon":0},{"id":"2568491421","title":"Oruka Therapeutics Shares Jump 20% to Eight-Month High After Co Announces Positive Early-Stage Study Results for Its Experimental Psoriasis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2568491421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568491421?lang=en_us&edition=fundamental","pubTime":"2025-09-17 21:35","pubTimestamp":1758116156,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nL3N3V40XZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2568454677","title":"Press Release: Oruka Therapeutics Announces $180 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2568454677","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568454677?lang=en_us&edition=fundamental","pubTime":"2025-09-17 13:02","pubTimestamp":1758085320,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Sept. 17, 2025  -- Oruka Therapeutics, Inc.  , a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity  financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthcare Fund, Blackstone Multi-Asset Investing, Commodore Capital, Cormorant Asset Management, Deep Track Capital, Fairmount, Great Point Partners, LLC, Palo Alto Investors, LP, Perceptive Advisors, Surveyor Capital , Venrock Healthcare Capital Partners, Woodline Partners LP and a leading life sciences investment firm, among others.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","ORKA","LENZ"],"gpt_icon":0},{"id":"2568545514","title":"Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2568545514","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568545514?lang=en_us&edition=fundamental","pubTime":"2025-09-17 13:00","pubTimestamp":1758085200,"startTime":"0","endTime":"0","summary":"Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/17/3151351/0/en/Oruka-Therapeutics-Announces-Positive-Interim-Phase-1-Results-for-ORKA-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1169589451.USD","LU1169590202.USD","PK","PD","BK4218","BK4139","BK4181","ORKA"],"gpt_icon":0},{"id":"2558643660","title":"Oruka Therapeutics Reports Q2 2025 Financials: Net Loss Widens to $24.6M, Driven by Increased Stock-Based Compensation","url":"https://stock-news.laohu8.com/highlight/detail?id=2558643660","media":"Reuters","labels":["dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558643660?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:04","pubTimestamp":1754942657,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on August 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDLYjw6f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","LU2210149790.SGD","LU2095319765.USD","BK4585","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","NDAQ","BK4588","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2558192660","title":"Oruka Therapeutics Inc -  Q2 EPS $-0.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2558192660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558192660?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:04","pubTimestamp":1754942640,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUAP6MY7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2554052776","title":"Oruka Therapeutics Inc  expected to post a loss of 49 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2554052776","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554052776?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:43","pubTimestamp":1753702985,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc  expected to post a loss of49cents a share - Earnings Preview Oruka Therapeutics Inc ORKA.OQ ORKA.O is expected to  report resultson July 30 (estimated) for the period ending Ju","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nL8N3TP0UI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}